Pages

Thursday, November 10, 2011

Galectin Therapeutics Reports Third Quarter and Nine Months 2011 Financial Results

Galectin Therapeutics Inc. (OTC: GALT) , the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the third quarter and first nine months, ended September 30, 2011. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the SEC. "In the third quarter, Galectin Therapeutics continued to build the foundation for the development of our carbohydrate-based therapie...continued
 

No comments:

Post a Comment